Aytu BioPharma Inc (AYTU)
1.54
-0.20
(-11.75%)
USD |
NASDAQ |
Nov 14, 16:00
1.54
0.00 (0.00%)
After-Hours: 20:00
Aytu BioPharma Revenue (Quarterly): 17.98M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 17.98M |
| March 31, 2024 | 17.99M |
| December 31, 2023 | 22.93M |
| September 30, 2023 | 22.10M |
| June 30, 2023 | 30.73M |
| March 31, 2023 | 22.73M |
| December 31, 2022 | 26.28M |
| September 30, 2022 | 27.66M |
| June 30, 2022 | 27.45M |
| March 31, 2022 | 24.20M |
| December 31, 2021 | 23.12M |
| September 30, 2021 | 21.90M |
| June 30, 2021 | 23.48M |
| March 31, 2021 | 13.48M |
| December 31, 2020 | 15.15M |
| September 30, 2020 | 13.52M |
| June 30, 2020 | 14.86M |
| March 31, 2020 | 8.156M |
| December 31, 2019 | 3.175M |
| September 30, 2019 | 1.440M |
| June 30, 2019 | 1.716M |
| March 31, 2019 | 2.378M |
| December 31, 2018 | 1.795M |
| September 30, 2018 | 1.432M |
| June 30, 2018 | 0.9251M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.607M |
| December 31, 2017 | 1.051M |
| September 30, 2017 | 1.076M |
| June 30, 2017 | 0.836M |
| March 31, 2017 | 0.894M |
| December 31, 2016 | 0.794M |
| September 30, 2016 | 0.698M |
| June 30, 2016 | 0.9373M |
| March 31, 2016 | 0.6684M |
| December 31, 2015 | 0.4694M |
| September 30, 2015 | 0.4874M |
| June 30, 2015 | 0.182M |
| March 31, 2015 | 0.0238M |
| February 28, 2015 | |
| November 30, 2014 | |
| August 31, 2014 | |
| May 31, 2014 | 0.001M |
| February 28, 2014 | |
| November 30, 2013 | |
| August 31, 2013 | |
| May 31, 2013 | 0.0018M |
| February 28, 2013 | |
| November 30, 2012 | |
| August 31, 2012 | 0.0018M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.175M
Minimum
Dec 2019
30.73M
Maximum
Jun 2023
19.84M
Average
22.10M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| enVVeno Medical Corp | -- |
| Bristol-Myers Squibb Co | 11.89B |
| Telesis Bio Inc | 1.55M |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.05M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.617M |
| Total Expenses (Quarterly) | 19.50M |
| EPS Diluted (Quarterly) | -0.82 |
| Enterprise Value | 5.853M |
| Gross Profit Margin (Quarterly) | 66.23% |
| Profit Margin (Quarterly) | -25.68% |
| Earnings Yield | -185.7% |
| Normalized Earnings Yield | -106.12 |